Form 4: Brainstorm Cell Therapeutics Executive Acquires Shares Through Restricted Stock Award

Uri Yablonka, EVP & Chief Business Officer of Brainstorm Cell Therapeutics, acquired 109,426 shares of common stock through a restricted stock award on March 11, 2024.

Summary

• Uri Yablonka, the EVP & Chief Business Officer of Brainstorm Cell Therapeutics, filed a Form 4 on March 13, 2024, reporting changes in beneficial ownership.
• On March 11, 2024, Yablonka acquired 109,426 shares of Brainstorm Cell Therapeutics common stock through a restricted stock award.
• The restricted stock awards (RSAs) were approved by the board of directors on March 11, 2024, as part of the company's ordinary course grant of equity awards.
• The RSAs will vest in equal yearly installments over two years, with vesting occurring on the first and second anniversary of the grant date.
• Following the transaction, Yablonka directly owns 126,969 shares of Brainstorm Cell Therapeutics common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock award) and doesn't contain information that would significantly sway investor sentiment positively or negatively. It's a neutral event in the context of the company's overall performance.

Positives

• The grant of restricted stock awards aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the restricted stock awards.

Management Comments

• The grant of restricted stock awards was approved by the board of directors as part of the Issuer's grant of equity awards in the ordinary course.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices at Brainstorm Cell Therapeutics.

Stakeholder Impact

• The stock award aligns the executive's interests with shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates

Keywords

Form 4, Beneficial Ownership, Restricted Stock Award, Equity Awards, Brainstorm Cell Therapeutics, BCLI, Uri Yablonka, EVP, Chief Business Officer